Trending Stock News

Organovo Holdings, Inc. (ONVO) Analysts See $-0.08 EPS

Organovo Holdings, Inc. (NASDAQ:ONVO) LogoInvestors sentiment increased to 1.21 in Q2 2018. Its up 0.50, from 0.71 in 2018Q1. It increased, as 6 investors sold Organovo Holdings, Inc. shares while 23 reduced holdings. 14 funds opened positions while 21 raised stakes. 21.04 million shares or 5.55% more from 19.93 million shares in 2018Q1 were reported.
Amer Financial has 251,500 shares. Wealthtrust Fairport Limited Liability accumulated 1,500 shares. Tiaa Cref Limited Liability reported 208,686 shares. Jpmorgan Chase invested 0% of its portfolio in Organovo Holdings, Inc. (NASDAQ:ONVO). Vanguard Group Incorporated Inc invested in 0% or 4.72M shares. Schwab Charles Invest Mgmt holds 468,632 shares. Lehman Financial Resource invested 0.13% in Organovo Holdings, Inc. (NASDAQ:ONVO). Two Sigma Securities Limited reported 15,498 shares stake. Iconiq Capital Limited Liability Com has 0% invested in Organovo Holdings, Inc. (NASDAQ:ONVO) for 13,100 shares. Hightower Advisors Ltd Llc has invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Citigroup invested in 0% or 19,492 shares. 200 were accumulated by Fincl Architects Incorporated. Cue Group Inc Inc stated it has 0.02% of its portfolio in Organovo Holdings, Inc. (NASDAQ:ONVO). Alliancebernstein Limited Partnership holds 104,950 shares. Renaissance Technology Limited Liability Corporation holds 0% or 445,800 shares in its portfolio.

Analysts expect Organovo Holdings, Inc. (NASDAQ:ONVO) to report $-0.08 EPS on November, 8.They anticipate $0.01 EPS change or 11.11 % from last quarter’s $-0.09 EPS. After having $-0.07 EPS previously, Organovo Holdings, Inc.’s analysts see 14.29 % EPS growth. The stock decreased 1.85% or $0.02 during the last trading session, reaching $1.06. About 753,648 shares traded or 33.01% up from the average. Organovo Holdings, Inc. (NASDAQ:ONVO) has declined 47.56% since October 24, 2017 and is downtrending. It has underperformed by 63.18% the S&P500.

Organovo Holdings, Inc., an early commercial stage company, creates and creates functional and three-dimensional human tissues for use in medical research and therapeutic applications. The company has market cap of $120.26 million. The firm develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. It currently has negative earnings. The Company’s 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.

More important recent Organovo Holdings, Inc. (NASDAQ:ONVO) news were published by: Nasdaq.com which released: “Organovo to Present at 2018 Cell & Gene Meeting on the Mesa” on September 26, 2018, also Streetinsider.com published article titled: “Organovo (ONVO) to Present New Preclinical Data on 3D Bioprinted Human Liver Tissues for Treatment of …”, Seekingalpha.com published: “Key events next week – healthcare” on September 28, 2018. More interesting news about Organovo Holdings, Inc. (NASDAQ:ONVO) was released by: Nasdaq.com and their article: “Organovo Announces Release Date for Fiscal Second-Quarter 2019 Financial Results” with publication date: October 18, 2018.

Organovo Holdings, Inc. (NASDAQ:ONVO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*